01—Abstract
Summary
Summary of the 10-Q filed October 31, 2025. Cited figures are marked; the original filing is the authoritative source.
Thermo Fisher Scientific Inc. (TMO) reported solid financial results for the nine months ended September 27, 2025, with total revenues increasing by 3% year-over-year to $32.34 billiona.
Net income attributable to Thermo Fisher Scientific Inc. grew to $4.74 billionb, a 5.3% increase from the prior year period. The company demonstrated strong operational execution, reflected in an increase in both GAAP and adjusted operating income margins, driven by significant productivity improvements across its segments. The company continued its strategic growth initiatives, including targeted acquisitions.
Notable acquisitions during the period include the Filtration and Separation business from Solventum Corporation and Olink Holding AB. Management also highlighted ongoing efforts to streamline operations through restructuring actions, primarily in the Laboratory Products and Biopharma Services segment. Despite some market headwinds, such as customer hesitancy in the academic and government sector and challenges in China's diagnostics and healthcare market, Thermo Fisher's diversified business model and strong execution in core markets like pharma and biotech have driven performance.
02—Key points
Key Highlights
- Total revenues for the nine months ended September 27, 2025, increased 3% to $32.34 billion, up from $31.48 billion in the prior year period.
- Net income attributable to Thermo Fisher Scientific Inc. rose to $4.74 billion for the nine months ended September 27, 2025, a 5.3% increase compared to $4.51 billion in the prior year.
- GAAP operating income increased by 3% to $5.49 billion for the nine months ended September 27, 2025.
- Adjusted operating income (non-GAAP) showed stronger growth, up 3% to $7.23 billion for the nine months ended September 27, 2025, with an improved adjusted operating income margin of 22.4%.
- The company made significant investments in acquisitions, including the Filtration and Separation business and Olink Holding AB, bolstering its Life Sciences Solutions segment.
- Restructuring and other costs amounted to $316 million for the nine months ended September 27, 2025, reflecting ongoing efforts to streamline operations.
- Diluted earnings per share (EPS) for the nine months ended September 27, 2025, were $12.53, an increase from $11.75 in the prior year period.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2025filed October 31, 2025Financial Statements
Q3 FY2025 against Q3 FY2024
| Line item | Q3 FY2025Q3 FY2024 | Change |
|---|---|---|
| Revenue | $11.12B$10.60B | +4.9% |
| R&D Expenses | $346.00M$346.00M | 0.0% |
| SG&A Expenses | $2.16B$2.10B | +3.1% |
| Operating Expenses | $9.18B$8.76B | +4.8% |
| Operating Income | $1.94B$1.84B | +5.6% |
| Net Income | $1.62B$1.63B | −0.5% |
| EPS (Basic) | $4.28$4.26 | +0.5% |
| EPS (Diluted) | $4.27$4.25 | +0.5% |
| Shares Outstanding (Basic) | 378.00M382.00M | −1.0% |
| Shares Outstanding (Diluted) | 378.00M384.00M | −1.6% |
05—Questions
Frequently Asked Questions
How did Thermo Fisher's revenue and profit perform year-over-year for the nine-month period?
For the nine months ended September 27, 2025, Thermo Fisher Scientific Inc. reported total revenues of $32.34 billion, a 3% increase from $31.48 billion in the same period last year. Net income attributable to Thermo Fisher Scientific Inc. increased by 5.3% to $4.74 billion, up from $4.51 billion in the prior year. GAAP operating income also saw a 3% increase, reaching $5.49 billion.
What are the key segments contributing to Thermo Fisher's performance, and are there any notable trends?
The company's performance is driven by four key segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. For the nine months ended September 27, 2025, Laboratory Products and Biopharma Services and Life Sciences Solutions were the primary contributors to organic revenue growth. While the pharma and biotech market showed strong demand, the academic and government market experienced a decline due to customer hesitancy, and the diagnostics and healthcare market faced headwinds in China.
Has Thermo Fisher been involved in any significant acquisitions or divestitures recently?
Yes, Thermo Fisher has been actively engaged in strategic acquisitions. Notable acquisitions during this period include the Filtration and Separation business from Solventum Corporation and Olink Holding AB, both of which are expected to strengthen its Life Sciences Solutions segment. The company is also pursuing a significant acquisition of Clario Holdings, Inc. for approximately $8.875 billion, which is expected to close by mid-2026 and will be integrated into the Laboratory Products and Biopharma Services segment.
What is the company's financial health concerning debt and liquidity?
As of September 27, 2025, Thermo Fisher Scientific Inc. had total debt of $35.68 billion. The company reported $1.98 billion in cash and cash equivalents and $1.56 billion in short-term investments. Management believes that its existing cash, future operating cash flow, and available borrowing capacity under its revolving credit facility are sufficient to meet its cash requirements for the foreseeable future, including at least the next 24 months. Free cash flow for the nine months ended September 27, 2025, was $3.32 billion.
06—Continue